USX:AZN - Astrazeneca plc (USD 40.12) 1 Followers Astrazeneca plc
Sector: Health Technology, Industry: Pharmaceuticals: Major

Add to WatchList

Set Alert


USD 40.12    -0.610 (-1.50%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

19 Jul 2019


Overview

19 Jul 2019

Day Change: -0.610 (-1.50%)

52 Wk Range: 35.3 - 43.295

Day's Range: 40.06 - 40.5899

Last Volume: 3,709,634

Current Yield: 3.41%

Open: USD 40.52

Close: USD 40.12

19 Jul 2019

Metric AZN S.Median
Beta 0.51 0.63
VaR 14.46 28
E.Shortfall 23.6 42.66
Liquidity 2.7M 43.29K

Fundamental


More from Yahoo

Screener

[Members Only]

Sign up for free to access most features of StocksCafe

Scorer

[Members Only]

Sign up for free to access most features of StocksCafe

Description

AstraZeneca PLC engages in the discovery, development, manufacture, and commercialization of prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. Its marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. It serves primary care and specialty care physicians through distributors and local representative offices. The company's pipeline includes 132 projects, of which 120 are in the clinical phase of development. It has collaboration agreements with Valeant Holdings Ireland, and Eli Lilly and Company; definitive agreement with Foundation Medicine, Inc.; strategic collaboration with FibroGen and Astellas; collaboration and license agreement with Celgene International Sarl; and license agreement with LEO Pharma A/S. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

General

CEO: Pascal Soriot

Headquarters: Cambridge

Employees: 59,700

Sector: Health Technology

Industry: Pharmaceuticals: Major

Useful Links
Homepage

Price Simulation

My Notes

You currently do not have notes about this stock.




Dividends Tax Rate
Tax Rate (%)

Min Commission (USD)


Past Transactions Add Transactions

You do not have past transactions for this stock.


Shared Portfolios Stats
All Shared Portfolios
0% holds AZN (0/188)
0% recent buy involves AZN (0/111)
0% recent sell involves AZN (0/68)

*recent means in the last 14 days.


Similar Stocks Biostar Pharmaceuticals Inc

Novartis AG

Tonix Pharmaceuticals Holding Corp

Glaxosmithkline plc

Retrophin Inc